Organogenesis Holdings Inc (ORGO)vsViatris Inc (VTRS)
ORGO
Organogenesis Holdings Inc
$2.44
+1.24%
HEALTHCARE · Cap: $317.74M
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 2435% more annual revenue ($14.30B vs $564.17M). ORGO leads profitability with a 6.6% profit margin vs -24.6%. ORGO earns a higher WallStSmart Score of 67/100 (B-).
ORGO
Strong Buy67
out of 100
Grade: B-
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.7%
Fair Value
$7.02
Current Price
$2.44
$4.58 discount
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 78.1% year-over-year
Attractively priced relative to earnings
Strong operational efficiency at 28.9%
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
6.6% margin — thin
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ORGO
The strongest argument for ORGO centers on Price/Book, Revenue Growth, P/E Ratio. Revenue growth of 78.1% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Profit Margin.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ORGO profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.39 — expect wider price swings.
ORGO is growing revenue faster at 78.1% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
ORGO scores higher overall (67/100 vs 50/100) and 78.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?